Test Price
2,800 AED✅ Home Collection Available
CYP7B1 Gene SPG5A Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CYP7B1 لمرض SPG5A بتقنية التسلسل الجيني المتقدم (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary | ملخص تنفيذي التحليل الجيني المتقدم لجين CYP7B1 باستخدام التسلسل من الجيل التالي يقدم أعلى معايير الدقة للتشخيص الوراثي للشلل التشنجي الوراثي من النوع 5A في الإمارات، مع التزام كامل بتعليمات هيئة الصحة بدبي لعام 2026 وقانون الفحص الجيني للقاصرين.
- ● 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited NGS processing with full gene coverage and clinical-grade variant interpretation.
- ● Premium Logistics – Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
- ● Telephonic Post-Test Clinical Guidance – Expert genetic counselors explain results and next steps in English or Arabic.
- ● Direct Billing Verification – WhatsApp +971 54 548 8731 to confirm coverage before collection.
Overview | لمحة عامة
CYP7B1 Genetic Test definitively diagnoses SPG5A hereditary spastic paraplegia by sequencing the entire CYP7B1 gene for pathogenic mutations—essential for any patient with unexplained lower‑limb stiffness or family history. This test follows the latest DHA‑mandated protocols and gives clinicians actionable genetic evidence to tailor neurological care.
يقدم هذا الفحص تشخيصاً جينياً دقيقاً للشلل التشنجي الوراثي SPG5A من خلال تحليل شامل لجين CYP7B1، مما يمكّن أطباء الأعصاب من وضع خطة علاجية شخصية وفق أعلى المعايير.
| Parameter | Our Test (CYP7B1 NGS) | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing with >99% analytical sensitivity and specificity | Targeted hot‑spot analysis; misses rare or novel variants |
| Method | Next Generation Sequencing (NGS) with Sanger confirmation | Sanger sequencing of limited exons |
| Turnaround Time | 3 to 4 Weeks | 6 – 10 Weeks |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Often non‑certified overseas labs |
Physician Insight & Safety Protocol
“As a neurologist, I must emphasise that this powerful genetic test provides a molecular diagnosis, but clinical correlation with a complete neurological exam and family history is irreplaceable. A positive result can guide early treatment and counselling, yet it never defines a patient’s destiny alone. Always involve a certified genetic counsellor before and after testing.”
– Dr. PRABHAKAR REDDY, DHA License 61713011
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic results are not a substitute for ongoing neurological management; changes in therapy require specialist review.
Exclusion Criteria & Emergency Red Flags
- This test is not intended for emergency diagnosis; acute onset of paralysis or vision loss requires immediate ER evaluation.
- Testing is contraindicated without pre‑test genetic counselling – a detailed pedigree must be drawn.
- Red Flags: Rapid neurological deterioration, sudden loss of ambulation, or new‑onset seizures — go to the nearest emergency department.
- Minors must have informed consent from a legal guardian as per CDS Law 2026 (UAE Minors).
- Data privacy is protected under UAE PDPL and Federal Decree‑Law No. 41 of 2024, Article 87.
Patient FAQ & Clinical Guidance | الأسئلة الشائعة
Q: What is the CYP7B1 genetic test and who needs it?
س: ما هو تحليل جين CYP7B1 ومن هم الأشخاص الذين يحتاجونه؟
The CYP7B1 NGS test detects mutations causing SPG5A hereditary spastic paraplegia in individuals with progressive leg stiffness.
This advanced NGS panel sequences all coding regions of the CYP7B1 gene. It is recommended for patients with gradually worsening spasticity, abnormal gait, or a positive family history. Neurologists, medical geneticists, and pediatric neurologists typically order this test to confirm SPG5A, differentiate it from other spastic paraplegias, and provide reproductive risk counselling.
يُكشف هذا التحليل الطفرات المسببة للمرض، وهو ضروري للمرضى الذين يعانون من تيبس الساقين التدريجي أو تاريخ عائلي للمرض. يوصي به أطباء الأعصاب وأطباء الوراثة لتأكيد التشخيص.
Q: How is the performed and what sample is required?
س: كيف يتم إجراء الفحص وما هي العينة المطلوبة؟
A simple blood sample (EDTA whole blood) or extracted DNA is required; next-generation sequencing analyzes the entire CYP7B1 gene.
We accept whole blood collected in an EDTA tube, purified DNA, or a drop of blood on an FTA card. Our VIP mobile phlebotomist visits your home (8 AM – 11 PM) using cold‑chain transport. No special diet or medication stop is needed. The sample is processed in our ISO‑certified lab, ensuring chain‑of‑custody from collection to report.
تُسحب عينة دم بسيطة بواسطة فريقنا المتنقل، ولا حاجة للصيام. يضمن التسلسل الجيني من الجيل التالي تغطية شاملة للجين.
Q: What do the results mean and how long does it take?
س: ماذا تعني النتائج وكم يستغرق صدورها؟
Results indicate pathogenic CYP7B1 variants linked to SPG5A; final report typically delivered in 3–4 weeks.
A positive report identifies the specific mutation(s) responsible for hereditary spastic paraplegia type 5A, allowing family cascade testing. Negative results do not rule out all genetic causes, so clinical follow‑up remains essential. Every report includes a clinician‑friendly interpretation and recommendation for a genetic counselling session. You will receive a telephonic consultation to explain findings in Arabic or English.
تصدر النتيجة خلال 3 إلى 4 أسابيع، وتُرفق بتقرير تفسيري سريري. النتيجة الإيجابية تؤكد الإصابة، بينما السلبية لا تستبعد الأسباب الجينية الأخرى.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians